Astra’s Covid-19 Vaccine Needs Another Trial to Assess EfficacySoriot said he didn’t expect the additional trial to hold up regulatory approvals in the U.K.
and European Union. Clearance from the U.S. Food and Drug Administration may take longer because the regulator is unlikely to approve the vaccine on the basis of studies conducted elsewhere, especially given the questions over the results, he said.
Authorization in some countries is still expected before the end of the year, he said.Astra and its CEO are facing scrutiny as the drugmaker responds to growing confusion over the vaccine.
The company’s late-stage data initially increased confidence that the world would soon have multiple shots to combat the pathogen, following positive.